Gynecologic oncologist at Arizona Oncology

Bradley Monk, MD, FACOG, FACS

This content originally appeared on our sister site, 

VB-111 is a targeted anticancer viral gene therapy that is based on a non-replicating, non-integrating adenovirus 5 vector that contains a transgene expressed solely in angiogenic blood vessels.

OncLive spoke with Bradley Monk, MD, FACOG, FACS, a gynecologic oncologist at Arizona Oncology, about the mechanism of action of VB-111 in patients with ovarian cancer.

The agent has a dual mechanism of action, Monk says. The agent targets endothelial cells, which causes vascular disruption and results in tumor starvation, and induces immune response through local inflammation, Monk concludes.

Videos

Bradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.

Bradley Monk, MD, FACOG, FACS

Articles

Mechanism of VB-111 in Treating Ovarian Cancer: Bradley Monk, MD, FACOG, FACS